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0022-2836/© 2009 Elsevier Ltd. Open accTo survive and colonise their various environments, including those used
during infection, bacteria have developed a variety of adaptive systems.
Amongst these is phage shock protein (Psp) response, which can be induced
in Escherichia coli upon filamentous phage infection (specifically phage
secretin pIV) and by other membrane-damaging agents. The E. coli Psp
system comprises seven proteins, of which PspA is the central component.
PspA is a bifunctional protein that is directly involved in (i) the negative
regulation of the psp-specific transcriptional activator PspF and (ii) the
maintenance of membrane integrity in a mechanism proposed to involve
the formation of a 36-mer ring complex. Here we established that the PspA
negative regulation of PspF ATPase activity is the result of a cooperative
inhibition. We present biochemical evidence showing that an inhibitory
PspA–PspF regulatory complex, which has significantly reduced PspF
ATPase activity, is composed of around six PspF subunits and six PspA
subunits, suggesting that PspA exists in at least two different oligomeric
assemblies. We now establish that all four putative helical domains of PspA
are critical for the formation of the 36-mer. In contrast, not all four helical
domains are required for the formation of the inhibitory PspA–PspF
complex. Since a range of initial PspF oligomeric states permit formation of
the apparent PspA–PspF dodecameric assembly, we conclude that PspA
and PspF demonstrate a strong propensity to self-assemble into a single
defined heteromeric regulatory complex.© 2009 Elsevier Ltd. Open access under CC BY license.Keywords: PspA; regulatory complex; σ54 transcription; PspF; phage shock
protein (Psp)Edited by M. GottesmanIntroduction
Bacteria can experience a multitude of stresses,
many of which have the potential to affect cell
integrity. To survive and colonise their environ-
ments, bacteria use a number of adaptive systems.
One such system found in a variety of bacterial
species is phage shock protein (Psp) response, which
can be induced in Escherichia coli upon filamentous
phage infection (specifically secretin pIV) and byresses:
@imperial.ac.uk.
hock protein; bEBP,
ess under CC BY license.other membrane-damaging agents.1–3 The psp reg-
ulon is conserved amongst enterobacteria and
usually comprises the pspABCDE operon and the
pspG gene, transcription of which is activated by
PspF (reviewed by Darwin3). Under normal growth
conditions, PspF activity is negatively regulated by
PspA.4–6 Following loss of membrane integrity
(potentially resulting in dissipation of proton motive
force), the negative regulation of PspF activity is
lost, enabling PspF to activate σ54-dependent
transcription from the two psp promoters pspAp
and pspGp.2,7–9 Maintenance of cell membrane
integrity is crucial for bacterial survival, especially
when bacteria are exposed to challenging conditions,
as is the case with eukaryotic tissue colonisation
during infection. For pathogens such as Salmonella
765PspA-PspF Regulatory Complexand Yersinia, the Psp response is clearly important
for their success as infectious agents.10,11 In spite of
the significance of the Psp response, the mechanistic
basis of its regulation is still poorly understood.
The transcriptional activator PspF is awell-studied
member of bacterial enhancer binding proteins
(bEBPs) belonging to the AAA+ (ATPases associated
with various cellular activities) protein family. PspF
functions as a higher-order oligomer (a hexamer)
and hydrolyses ATP during its role as a transcrip-
tional activator.12,13 Although bEBPs are usually
composed of three domains (a regulatory domain, an
AAA+ ATPase domain, and a DNA binding do-
main), PspF lacks a regulatory domain. Instead, its
activity is negatively controlled by PspA acting in
trans.4–7 As is the case for many bEBPs, the catalytic
AAA+ domain of PspF (PspF1–275) is necessary and
sufficient to activateσ54-dependent transcription; for
PspF1–275, its activity has been shown to be regulated
by PspA both in vivo and in vitro.2,4–6,14,15
PspA is a bifunctional protein that is directly
involved in (i) the negative regulation of PspF and
(ii) the maintenance of membrane integrity. PspA is
predicted to be a coiled-coil protein comprising four
α-helical domains (HD1–HD4; Fig. 1)4,5 and inter-
acts with the inner membrane proteins PspB and
PspC, as well as with PspF (Adams et al.16 and
reviewed by Darwin3). The mechanism by which
inducing signals (potentially a change in proton
motive force or membrane organisation) are sensed
and transmitted to PspA is not clear, but appears to
usually involve PspBC.2 Neither the precise role of
each of the Psp proteins nor the mechanistic basis of
Psp-mediated membrane repair and PspF negative
regulation is known. Apparently, PspB and PspC
function as inner membrane sensors of the stress
signal, which, during stress conditions, transduce anFig. 1. Predicted organisation of PspAFL and the PspAfragm
protein consisting of four α-helical domains: HD1 (residues 1
HD4 (residues 187–222), as determined by computer analyse
PspAfragments: PspA1–67 (HD1), PspA68–110 (HD2), PspA1–110 (H
HD3), and PspA68–222 (HD2–HD3–HD4), with correspondinginducing signal to PspA via protein–protein
interactions.3 “Activation” of PspA somehow alters
the PspA–PspF interaction, relieving PspF inhibition
and thereby allowing activation of psp transcription.
Structural studies have previously established
that purified PspA can form a 36-mer ring compris-
ing nine tetramers.17 Recently, Standar et al. have
reported a second PspA oligomeric organisation,
called the “PspA scaffold,” that has been proposed
to be important for the maintenance of membrane
integrity.18 Earlier functional studies have deter-
mined that PspA acts as an effector by interacting
directly with membrane lipids to repair membrane
proton leakage.19 Elderkin et al. demonstrated that
PspA acts as a negative regulator by directly binding
PspF in an interaction that is dependent on the
surface-exposed residue W56 (of PspF).5,6 Not all
four putative α-helical domains of PspA are
required to interact with and to negatively regulate
PspF.5 PspA inhibition of PspF ATPase activity6
probably involves the repositioning of residue N64
(of PspF), which is thought to be involved in the
sensing and positioning of the γ-phosphate of
ATP.20 Analysis of the structural features and
activity of PspA can also contribute to an under-
standing of the function of VIPP1, a PspA homo-
logue that is crucial for thylakoid biogenesis and
essential for photosynthesis.21 In addition, several
common extracytoplasmic stresses known to induce
the Psp response in E. coli are reported to upre-
gulate PspA expression in other Gram-negative and
Gram-positive bacteria, archebacteria, and plants
(Bidle et al.22 and Vrancken et al.23 and reviewed by
Darwin3).
The precise relationship between PspA and PspF is
poorly understood, especially at the level of the self-
association state of PspA and PspF within theents used in this study. PspA is predicted to be a coiled-coil
–67), HD2 (residues 68–110), HD3 (residues 111–186), and
s (see Materials and Methods). PspAFL (full length) and
D1–HD2), PspA1–186 (HD1–HD2–HD3), PspA68–186 (HD2–
ly numbered residues, are presented.
766 PspA-PspF Regulatory Complexinhibitory complexes. Indeed, the organisation of the
repressive complex that forms between both proteins
is not characterised. Whether the PspA–PspF inter-
action is dependent on particular nucleotide-bound
states of PspF (which might therefore impact on the
ATPase activity of PspF) and whether the negative
regulation of PspF activity affects the interaction
between PspF and σ54 remain unknown. To inves-
tigate the nature of the molecular mechanism
responsible for PspA–PspF negative regulation, we
chose an in vitro approach using purified proteins.
We established that PspA negative regulation of
PspF ATPase activity is the result of a cooperative
inhibition, and that the PspA/PspF ratio found
within the inhibitory PspA–PspF co-complex is
near unity. In addition, we have determined what
features of PspA and PspF are required for the
formation of the PspA–PspF regulatory complex and
its inhibited state, and we have demonstrated that
some activities of PspF (ultimately used for tran-
scription activation) are not inhibited by PspA.Results
The inhibitory activities of PspAfragments are due
to direct binding interactions with PspF
The apparent organisation of PspA (predicted to
be four α-helical domains, labelled HD1–HD4; seeFig. 2. PspAfragments interaction assays. PspA–PspF affin
PspF1–275 applied to a Ni-NTA column preloaded with either H
fractions were loaded on SDS-PAGE and stained with Coom
absence of His-PspA is shown as control. FT: flow through; WFig. 1) lends itself to a protein fragmentation
approach, with the potential to separate out deter-
minants required for regulatory (modulation of PspF
activity) and effector (maintenance of cell membrane
integrity) functions by establishing the contributions
of each of the HD to the functionalities of PspA.
Following purification of PspAFL (full length) and
PspAfragments [PspA1–67 (HD1), PspA68–110 (HD2),
PspA1–110 (HD1–HD2), PspA1–186 (HD1–HD2–
HD3), PspA68–186 (HD2–HD3), and PspA68–222
(HD2–HD3–HD4)] (Fig. 1), we tested the ability of
these proteins to interact with the AAA+ domain of
PspF (herein termed PspF1–275WT) and to inhibit its
ATPase activity. Previous studies have shown that
PspAFL, PspA1–110, PspA1–186, PspA68–186, and
PspA68–222 interact with PspF1–275WT
5 using a
native-gel-based nonequilibrium method that is
sensitive to buffer and gel-running conditions. One
aim of this studywas to estimate the stoichiometry of
PspA and PspF within the PspA–PspF regulatory
complex. To address this issue, we employed an
equilibrium method based on affinity chromatogra-
phy to measure direct binding interactions between
PspF and either His-PspAFL or His-PspAfragments
(Materials and Methods; Fig. 2). Using this method,
we observed an interaction between PspF1–275WT
and PspAFL, PspA1–110, PspA1–186, PspA68–186, and
PspA68–222, but not with the PspA1–67 or PspA68–110
fragments. However, we note that the interaction
between PspA68–186 and PspF1–275WT is weaker than
the interaction with other PspAFL or PspAfragments.ity chromatography using a saturating concentration of
is-tagged PspA or PspAfragments (as indicated). The eluted
assie blue. The amount of PspF1–275 after elution in the
2 and W3: wash volumes 2 and 3; E: elution.
767PspA-PspF Regulatory ComplexControl reactions verified that PspF1–275WT could
not bind specifically to the column in the absence
of His-tagged PspAFL (or PspAfragments), and that
no clear interactions with either His-PspAFL or His-
PspAfragments were detected in the presence of
PspF1–275W56A (the form of PspF that is unable
to interact with PspA).
PspF ATPase inhibition
Having demonstrated that the majority of PspA
fragments were able to interact directly with
PspF1–275WT (but not with PspF1–275W56A), we
examined whether these interactions were effective
in inhibiting PspF ATPase activity. We first deter-
mined which concentration of PspF1–275WT or
W56A to use by establishing for the two proteins
the titration curve of the ATPase activity as a
function of protein concentration (Fig. 3). We chose
to use 2 μM PspF1–275WT or W56A for inhibition
studies, based on knowledge of the concentration
dependency of the ATPase activity.12 We then used
different concentrations of PspAFL and PspAfragments
and observed their effects on the PspF ATPase
activity. As shown in Fig. 3, PspAFL, PspA1–186,
PspA1–110, and PspA68–222 inhibit the PspF ATPase
activity with differing efficiencies. Inhibition of the
ATPase activity by PspA1–110 and PspA68–222 is only
clearly observed when these fragments are present
in large excess over PspF. With the HD4 deletion
variant (PspA1–186), some ATPase inhibition occurs
at a PspF/PspA ratio of 1:1, whereas in the presence
of PspAFL, significant inhibition is observed at a
PspF/PspA ratio of 1:2, suggesting a higher affinity
of PspA1–186 for PspF than for PspAFL (Fig. 3).
However, when the concentration of the PspAFL or
PspAfragments is increased (to 1:2 or 1:2.5), the
ATPase activity is more strongly inhibited by PspAFL
than by PspA1–186, suggesting a cooperative inhibi-
tion by PspAFL, whereas PspA1–186 inhibition appears
noncooperative. Inhibition of PspFATPase activity by
PspA may therefore require residues 187–222 (HD4)Fig. 3. PspAfragments inhibitory effect on PspF ATPase act
activity performed at 37 °C in the presence of 2 μM PspF1–275
length or fragments, as indicated). The results are expressed asto establish a functional inhibitory cooperativity, but
not a cooperativity for binding to PspF.
From these results, we conclude that the differ-
ent PspA fragments have a range of affinities for
PspF and function to decrease (to varying extents)
PspF1–275WT ATPase activity (Fig. 3). We note that
fragments that failed to interact with PspF (PspA1–67,
PspA68–110, and PspA68–186) in affinity chromatogra-
phy experiments (see Fig. 2) were unable to
significantly decrease the PspF ATPase activity.
Notably, the fragment (PspA1–186) that exhibited the
strongest affinity for PspF is not the most effective at
inhibiting the ATPase activity of PspF, suggesting a
mechanism of PspF inhibition more complex than
that resulting from simple binding. Indeed, using
PspAFL, we detect a clear cooperative inhibition of
PspF ATPase activity. These results strongly infer
that rather than a single HD within PspA being
responsible for the inhibitory activity of PspA, PspA
HDs function together to efficiently regulate PspF
ATPase activity.
Formation of the regulatory PspA–PspF
complex is not dependent on the
nucleotide-bound state of PspF
We have previously shown that PspF activity is
dependent on the nucleotide-bound state.12 Having
validated the affinity-based method for assaying the
direct binding of PspA to PspF1–275WT, we exam-
ined whether the nucleotide-bound state of PspF
could affect its capacity to bind PspA. Using the
affinity binding method, we assayed the interaction
between PspF1–275WT and either His-PspAFL or His-
PspAfragments when either ATP, ATPγS, AMPPNP,
ADP, AMP, or no nucleotide was present in the
binding and wash buffers. In each case, we observed
a very similar (to Fig. 2) PspA–PspF binding
interaction profile (data not shown). We therefore
conclude that the nucleotide-bound state of PspF
does not alter the binding interactions between
PspA and PspF required for co-complex formation.ivity. The effect of PspAfragments on the PspF1–275 ATPase
(WT or W56A) and different concentrations of PspA (full
percentage of PspF1–275WT activity in the absence of PspA.
768 PspA-PspF Regulatory ComplexWe next investigated directly whether the interac-
tion between PspA and PspF could change the
nucleotide binding affinity of PspF. Using a filter-
based nucleotide binding assay, we determined the
ATP and ADP binding properties of PspF1–275WT (as
performed by Joly et al.20,24) and did not observe any
significant difference in the presence of PspAfragments
(data not shown). We conclude that PspA binding
(to PspF) does not significantly affect the nucleotide
binding activity of PspF.
36-mer formation is an intrinsic property of
PspAFL: Determinants of PspA oligomerisation
Having established that the majority of purified
PspAfragments are functional in vitro, we addressed
the question of the contribution of each of the
putative HDs to the formation of the reported (in the
case of PspAFL) PspA 36-mer.
17 Using gel filtration,
which separates proteins and protein complexes as a
function of their apparent molecular mass based on
their apparent stokes radius, we analysed the
elution profiles obtained for each of the purified
PspAfragments (Fig. 4). Based on the predicted
molecular masses of PspAFL (28 kDa), PspA1–67
(10 kDa), PspA68–110 (8 kDa), PspA1–110 (15 kDa),
PspA1–186 (24 kDa), PspA68–186 (17 kDa), and
PspA68–222 (20 kDa), and the column calibrationFig. 4. Oligomerisation state of PspAfragments. Gel-
filtration profiles of 50-μl samples containing 30 μM
PspAfragments chromatographed through a Superose 6
column at 4 °C. The column was calibrated with globular
proteins (the elution volumes of which are indicated by
gray lines): thyroglobulin (669 kDa), apoferritin (443 kDa),
β-amylase (200 kDa), bovine serum albumin (66 kDa), and
carbonic anhydrase (29 kDa), under the same conditions.with globular proteins (see Materials and Methods),
we estimated the apparent oligomeric forms of the
different PspAfragments. For PspAFL, we observed a
peak with an elution volume corresponding to an
apparent 90-mer (Fig. 4). Although this does not
appear to directly correlate with the 36-mer in gel
filtration, we use globular proteins to calibrate the
system; the PspA36-mer ring is not a globular protein,
so based on its apparent stokes radius, we expect the
apparent molecular mass of PspA to be much larger
than that of a 36-mer. For simplicity, we now refer to
the PspAFL oligomeric state as a 36-mer. In the
presence of PspAfragments (Fig. 4), we observed elution
volumes corresponding to apparent molecular
masses lower than that of PspAFL: PspA68–110 (an
apparent dimer), PspA1–110 (an apparent dimer),
PspA1–186 (an apparent dimer), PspA68–186 (an appar-
ent hexamer), and PspA68–222 (an apparent hexamer).
From the gel-filtration data, we conclude that
formation of the apparent higher oligomeric state
is an intrinsic property of PspAFL that involves
more than one HD. Our data suggest the follow-
ing: HD2–HD3 are responsible for hexamer forma-
tion (PspA68–186), and HD1 seems to modulate
HD2–HD3-dependent hexamer formation, thus
leading to dimers when present (PspA68–186 versus
PspA1–186). When HD4 is present with HD1–HD2–
HD3 (PspA1–186 versus PspAFL), formation of the
36-mer can occur. We thus conclude that HD4
seems to be required to overcome the negative
effect of HD1 on HD2–HD3.
PspA–PspF regulatory complex has a near-unity
protein ratio
Having shown that HD1–HD4 of PspA are
important for the formation of the native 36-mer
(observed with PspAFL), and that the majority of
PspAfragments were able to interact with PspF and to
inhibit its ATPase activity, we next analysed the
type of complex formed between PspA and PspF.
Clearly, PspAFL can form an apparent higher-order
oligomer (36-mer; Fig. 4), but the number of PspA
subunits within the PspA–PspF regulatory complex
is as yet unknown. To address this question, we
performed gel-filtration experiments comparing the
different elution profiles of either PspAFL alone or
PspF1–275WT alone to that of a mixture of PspAFL
and PspF1–275WT (incubated for 15 min at 4 °C prior
to loading on the gel-filtration column; Fig. 5a).
In the mixed sample, we observed a distinct
PspF1–275WT·PspAFL complex (apparent molecular
mass, 384 kDa), which elutes with an apparent
molecular mass lower than that of PspAFL alone (36-
mer) yet higher than that of PspF alone (hexamer; Fig.
5a). Analysis of the fractions by SDS-PAGE demon-
strated the presence of PspAFL and PspF1–275WT
proteins in this new peak (Fig. 5b). To estimate the
ratio of PspA–PspF protein present in the complex, we
used SDS-PAGE and loaded different concentrations
of His-PspAFL and PspF1–275WT proteins (Fig. 5c; data
not shown). Although the quantities of the proteins
loaded in the gel were very similar, the intensities of
Fig. 5. PspA–PspF regulatory complex composition. (a) Gel-filtration profiles of 50-μl samples containing 30 μM
PspAFL±20 μMPspF1–275WT orW56A (as indicated) chromatographed through a Superose 6 column at 4 °C. (b) Fractions
corresponding to the elution profile PspF1–275WT+PspAFL were loaded on SDS-PAGE and stained by Coomassie blue. (c)
SDS-PAGE showing the loading of different quantities of PspAFL and PspF1–275WT, Coomassie stained and used as
reference for protein ratio estimation. (d) Gel-filtration profiles of 50-μl samples containing 30 μM PspA1–186±20 μM
PspF1–275WT or W56A (as indicated) chromatographed through a Superose 6 column at 4 °C. (e) Gel-filtration profiles of
50-μl samples containing 30 μM PspA68–222±20 μM PspF1–275WT or W56A (as indicated) chromatographed through a
Superose 6 column at 4 °C. The column was calibrated with globular proteins (the elution volumes of which are indicated
by gray lines): thyroglobulin (669 kDa), apoferritin (443 kDa), β-amylase (200 kDa), bovine serum albumin (66 kDa), and
carbonic anhydrase (29 kDa), under the same conditions.
769PspA-PspF Regulatory ComplexCoomassie staining appear to be different (however,
we note that PspF1–275WT is more preferentially
stained than His-PspAFL). A similar difference in
stain intensity is seen in the fraction corresponding to
the peak containing the PspA–PspF complex, sug-
gesting a 1:1 PspF/PspA protein ratio in this
complex. Based on the estimated protein ratios from
the stained SDS-PAGE and the apparent molecular
mass of the complex, we estimated the protein
stoichiometry of this new complex to be close to six
PspAFL subunits and six PspF1–275WT subunits (Fig.
5b). No PspF was detected in the void volume
fraction, suggesting that the PspF is only bound toPspA in a co-complex that is close to a dodecamer. As
negative control, we used PspF1–275W56A (which
cannot interact with PspA) in the gel-filtration assays
and were unable to observe the formation of the co-
complex with PspA, since the gel-filtration profiles
remained identical with those of PspF1–275W56A and
PspAFL alone (Fig. 5a).
PspAfragments form PspA–PspF regulatory
co-complexes
We then tested whether discrete regulatory co-
complexes could be observed in the presence of
Fig. 6. PspA–PspF regulatory complex formation is not
dependent on the oligomeric state of PspF. Gel-filtration
profiles of 50-μl samples containing 30 μMPspAFL±20 μM
PspF1–275 (WT, W56A, K42A, or R168A) were chromato-
graphed through a Superdex 200 column at 4 °C. The
position of the PspA–PspF co-complex is indicated by the
black line. In this column, PspA alone elutes in the void
volume. The column was calibrated with globular
proteins: thyroglobulin (669 kDa), apoferritin (443 kDa),
β-amylase (200 kDa), bovine serum albumin (66 kDa), and
carbonic anhydrase (29 kDa), under the same conditions.
770 PspA-PspF Regulatory ComplexPspAfragments using the same gel-filtration approach
as with PspA1–186 mixed with PspF1–275WT. In this
case, we observed a similar regulatory co-complex
PspF1–275WT·PspA1–186 (apparent molecular mass,
358 kDa) comparable to that seen with PspAFL
(apparent molecular mass, 384 kDa; Fig. 5a and d).
Interestingly, the difference between the apparent
molecular masses of the two co-complexes (384–
358 kDa=26 kDa) corresponds to six times the
molecular mass of HD4, which is absent in PspA1–186
(6×4 kDa=24 kDa). We conclude that PspA1–186
forms a regulatory complex with PspF at a molar
ratio close to 6:6. Therefore, formation of the
regulatory co-complex appears to be independent
of the ability of PspA to form the higher-order
oligomeric complex (36-mer), since PspA1–186 is an
apparent dimer, suggesting some form of codepen-
dence between PspA and PspF for the formation and
organisation of the hetero near-dodecameric co-
complex. Similar results were obtained with the
PspA1–110 fragment, and the co-complex formed
with PspF was again shifted (in terms of elution
volume)—this time the difference in the apparent
molecular mass corresponded to six times the
molecular masses of HD3–HD4 (which are absent
in the PspA1–110 fragment; data not shown).
HD1 is important for the formation of the native
PspA–PspF regulatory co-complex
We have shown that, with the exception of HD1
alone (PspA1–67) or HD2 alone (PspA68–110), all the
PspAfragments tested were able to interact with PspF
and to inhibit its ATPase activity. However, we note
that HD2–HD3 (PspA68–186) alone only weakly
interacts with PspF and has no inhibitory effect on
ATPase activity. Surprisingly, when we conducted
the gel-filtration experiments using PspA68–222 (Fig.
5e) or PspA68–186 (data not shown), we observed a
PspF1–275WT·PspA68–222 co-complex very different
from that observed with PspAFL. The apparent
molecular mass of the PspF1–275WT·PspA68–222 co-
complex is 55 kDa, consistent with a heterodimer
(1:1) and not with a heterododecamer (6:6). From
these observations, we propose that HD1 of PspA is
not necessary for binding PspF, but plays an
important role in the formation of the regulatory
hetero near-dodecameric co-complex observed be-
tween PspF and PspAFL.
PspA–PspF regulatory co-complex is not
dependent on the initial oligomeric state of PspF
PspAFL, PspA1–186, and PspA1–110 bind PspF1–275WT
to form regulatory hetero near-dodecameric co-
complexes independent of the ability of PspA1–186
or PspA1–110 to form higher-order oligomeric struc-
tures. The organisation of PspA in the regulatory co-
complex with PspF clearly cannot be that of the
36-mer form. We next addressed whether the
oligomeric state of PspF could affect the formation
of the regulatory co-complex. Using a Superdex 200
column to achieve a greater resolution between thePspA–PspF regulatory co-complex and the PspF
hexamer elution volumes (compare Figs. 5a and 6),
we initially reproduced the observation that the PspA–
PspF co-complex consists of an apparent 6:6 ratio of
PspA/PspF (Fig. 6). We then performed similar
experiments with different forms of PspF previously
reported as monomeric/dimeric (PspF1–275K42A) or
constitutively hexameric (PspF1–275R168A) species.
25
Notably, the PspF1–275K42A and PspF1–275R168A co-
complexes formed with PspA eluted at a volume
similar to that observed with PspF1–275WT. We
conclude that the initial oligomeric state of PspF
does not prevent the formation of the near-dodeca-
meric PspA–PspF regulatory co-complex.
PspA does not inhibit PspF from interacting
with σ54
PspF transiently associates with the closed pro-
moter complex in its ATP-bound state, but can be
stably “trapped” in association with the closed
complex using the ATP transition state analogue
ADP-AlF.26 We considered whether PspA negative
regulation might function by preventing PspF from
interacting with σ54. To address this possibility, we
performed “trapping” experiments using radio-
Fig. 7. PspA–PspF regulatory complex can bind σ54. Native gel migration of “trapped” radiolabelled σ54 complexes
containing PspF1–275WT or PspF1–275W56A and PspA (full length or fragments, as indicated). DNA complexes were
detected by autoradiography.
771PspA-PspF Regulatory Complexlabelled σ54 to follow the formation of the
PspF·σ54·ADP-AlF complex (Fig. 7). We observed
that, in the presence of PspAFL or PspA1–186, the
PspF·σ54·ADP-AlF complex was supershifted in a
PspAFL or PspA1–186 concentration-dependent
manner, in direct agreement with the different
affinities of these fragments for PspF determined
in the ATPase inhibition assay. The PspA-depen-
dent supershifts were dependent on residue W56
and were therefore the result of specific PspA–
PspF interactions. We conclude that PspA does
not obviously inhibit the binding interaction
between PspF and σ54, suggesting that PspA,
when bound to PspF, does not occlude the σ54
binding site to achieve inhibition.Discussion
Studying the contributions of the PspA HDs to (i)
self-association, (ii) PspF co-complex formation, and
(iii) PspF negative regulation is important in
establishing the switching mechanism between the
regulatory function and the effector function of
PspA. Previous studies have shown that PspA can
form different oligomeric complexes in vitro (a 36-
mer and a “scaffold complex”7,18), and that the PspA
36-mer can directly interact with membrane lipids to
restore membrane integrity and to prevent proton
leakage,19 unlike the monomeric form of PspA. In
this study, using an in vitro approach, we demon-
strate that PspA negative regulation of PspF ATPase
activity is the result of a cooperative inhibition. We
also establish that all four putative HDs of PspA are
important in supporting the formation of the higher
oligomeric form of PspA (36-mer). We show that the
regulatory complex formed between PspA and PspF
is near-dodecameric and likely comprises six PspA
subunits and six PspF subunits. In addition, we
establish that formation of this co-complex is not
dependent on the initial oligomeric state of PspF
(and/or the nucleotide-bound state of PspF) or on
the ability of PspA to form the 36-mer, but depends
largely on the presence of HD4 (of PspA). Taken
together, these results suggest that regulation of
PspA activity could be achieved by altering the level
of PspA self-association, which in turn is dependenton particular HDs. Interactions between different
PspF and PspA oligomeric states (both higher and
lower) yielded a near-dodecameric co-complex,
suggesting that the final heteromeric complex
arrived at is relatively stable and is the favoured
configuration.
Regulation of the PspA–PspF interaction
Using the fragmentation approach, we have
shown that all four putative HDs of PspA are
important in the formation of the 36-mer (thought to
represent the effector complex). We show that
deleting at least one of these HDs drastically affects
the organisation of the PspA oligomer (i.e., the 36-
mer is no longer apparent). From the gel-filtration
results, we propose that HD1 acts as a negative
regulator of the oligomerisation activity of HD2–
HD3 (of PspA), which form a hexamer in the
absence of HD1 and a dimer in its presence. In
addition, HD4 has a direct effect on the oligomer-
isation of PspA when HD1 is present, suggesting
that the inhibitory activity of HD1 is suppressed by
HD4. We have shown that the binding interactions
between PspA and PspF required for co-complex
formation are not dependent on the ability of PspA
to form the 36-mer. Furthermore, the resulting co-
complexes had reduced PspF ATPase activity,
suggesting that formation of the PspA 36-mer is
not necessary for the formation of the repressive co-
complex between PspA and PspF (Fig. 8). The PspA
36-mer is most probably the effector complex and is
not expected to have a direct regulatory role with
respect to control of PspF ATPase activity.
Interconnectivity between PspA–PspF in the
regulatory co-complex organisation
We demonstrate that PspA interacts with PspF,
and that this interaction promotes the formation of a
hetero near-dodecamer co-complex likely formed of
six PspA subunits and six PspF subunits. Using
PspF variants differing in their degree of self-
association, we show that the initial oligomeric
state of PspF does not prevent the formation of the
final regulatory co-complex. This last point is
interesting and significant, since we have previously
Fig. 8. Summary of PspA and
PspA–PspF interactions. PspF exists
in equilibrium between a dimer and
a hexamer. The PspF hexamer is
active for ATPase and σ54-depen-
dent transcription activation of the
psp regulon. PspA can form a
higher-order oligomer (36-mer)
but, in the presence of PspF, forms
a much smaller co-complex. The
PspA–PspF regulatory co-complex
is composed of approximately six
PspA subunits and six PspF sub-
units, and formation of this com-
plex is not dependent on the ability
of PspA to form a 36-mer, but is
dependent on PspA HD1.
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inactive dimeric form and an active hexameric
form.12,25 Hence, it was formally possible that
regulation of PspF ATPase activity by PspA could
have occurred at the level of regulation of the self-
association activity of PspF (since the hexameric
form is required for activity), as is the case for other
EBPs containing an amino-terminal regulatory
domain.27 Strikingly, since we now show that the
regulatory complex is formed of approximately six
PspF subunits and six PspA subunits, it strongly
argues against an ATPase inhibition mechanism in
which PspA exerts negative control by forcing PspF
to remain dimeric. The organisation of the PspF
subunits in the PspA–PspF co-complex is probably
sufficiently different from the one in the active PspF
hexamer to cause loss of ATPase activity, but not the
ability to interact with σ54 (where PspF1–275 is
expected to be a hexameric ring28). We show that
PspF can affect the organisation of PspA in the
regulatory co-complex, and that HD1 of PspA also
affects the organisation of the PspA–PspF complex.
Interestingly, the PspA68–222 fragment (which is
missing HD1) is able to interact with PspF and to
inhibit its ATPase activity, but the stable PspA–PspF
complex formed is an apparent heterodimer. These
data suggest that PspA can indeed change the PspF–
PspF oligomerisation interface (used for forming the
ATPase active PspF hexamer) and, in so doing, alters
the presentation of key determinants required for
ATPase activity that are also localised at this
interface.13,29 These results suggest a complex
codependency between PspA and PspF that leads
to a stable near-dodecameric co-complex with
inhibited PspF ATPase activity. The interconnectiv-
ity between PspA and PspF in the formation of a
regulatory dodecameric co-complex with six PspF
subunits may be an important requirement for the
rapid release of PspA-imposed negative control.The role of PspA in Psp regulation and
effector function
Our new observations provide insights into the
control of the Psp system, which uses a regulation
mechanism known to be important in bacterial
virulence.3,10,11,30 Under nonstress growth condi-
tions, PspA negatively regulates PspF activity to
maintain a low-level expression of the Psp system
prior to its induction. Under stress conditions, the
psp-inducing signal is expected to promote a change
in the PspA–PspF interaction. PspF would then be
able to activate transcription of the psp regulon. The
amount of PspA in the cell will increase markedly,
whereas the amount of PspF remains constant.9,31
Increasing levels of PspA (under inducing condi-
tions) would promote formation of the large 36-mer
PspA complex, which is proposed to interact with
the inner membrane to prevent proton leakage.19
The oligomeric form of PspA under inducing
conditions may be such that it can no longer inhibit
PspF functionality. A signal to maintain the non-
repressive form of PspA probably exists, and we
speculate that additional factors such as PspB and
PspC could be involved in preventing the repressive
PspA–PspF co-complex from forming or in convert-
ing a repressive PspA–PspF complex into a non-
repressive one by causing its reorganisation. PspB
and PspC, which directly interact with PspA, have a
crucial role in inducing the Psp response as positive
control proteins and, like PspA, are upregulated
under psp-inducing conditions.3 It is therefore
formally possible that a PspABC complex “decays”
to allow the formation of the repressive PspA–PspF
regulatory co-complex. The in vitro cooperativity
inhibition of PspF ATPase activity observed as a
function of PspA concentration may be related to
setting the rate of transition between the repressed
state and the nonrepressed state of PspF.
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Plasmids
pET28b+-based plasmids pSLE18A, pSLEPspA1-67,
pSLEPspA1-110, pSLEPspA1-186, pSLEPspA68-186, and
pSLEPspA68-222 encode the full-length PspA and PspA
fragments PspA1–67, PspA1–110, PspA1–186, PspA68–186, and
PspA68–222, respectively, as amino-terminal 6His-fused
proteins.5 To construct the plasmid pGJ52 encoding
PspA68–110 fragment, we used the template pPB10, the
primers PspA-68-F-NdeI 5′-CATATGGAGGTTGAATGG-
CAGGAAAAAGCCG-3′ and PspA-110-R-BamHI 5′-
GGATCCCAGCGTCACTTCATGTTCCAGGG-3′, and
PCR. The DNA fragment obtained contained a NdeI
restriction site and a start codon at its 5′-end, and a BamHI
and stop codon at its 3′-end flanking the pspA sequence
encoding PspA68–110. This NdeI-BamHI DNA fragment
was cloned into a pGEM-T Easy vector and then subcloned
into pET28b+ digested with NdeI-BamHI, creating pGJ52.
Nucleotides
ATP, AMPPMP, ATPγS, AMP, and ADP were obtained
from Sigma at the highest purity level available. Radio-
labelled nucleotides were purchased from Perkin-Elmer.
Protein structure prediction
We submitted the amino acid sequence of E. coli PspA to
different structure prediction programmes (nnPredict,
Predator, and Coiled-coil prediction), the results of which
are summarised in Fig. 1. Note that we only assigned the
“predicted structure” for each amino acid when all three
software programs gave the same putative structure.
Protein purification
Full-length PspA or fragments were purified by affinity
chromatography, as described by Elderkin et al.5 The
purified protein was dialysed overnight at 4 °C against a
final storage buffer [20 mM Tris–HCl (pH 7.5), 200 mM
NaCl, 75 mM NaSCN, 0.005% 3-[(3-cholamidopropyl)
dimethylammonio]propanesulfonic acid, and 5% glycerol]
and frozen at −80 °C. PspF1–275WT and variants W56A,
K42A, and R168A encoded by pET28b+-based plasmids
were purified as described in Joly et al.12 The proteins were
stored in buffer [20 mM Tris–HCl (pH 8.0), 50 mM NaCl,
1 mM DTT, 0.1 mM ethylenediaminetetraacetic acid, and
5% glycerol] and frozen at −80 °C. σ54 and HMK-σ54 were
purified as described by Cannon et al.32 and stored at
−80 °C in 20 mM Tris–HCl (pH 8.0), 200 mM NaCl,
0.1 mM ethylenediaminetetraacetic acid, 1 mM DTT, and
50% glycerol. E. coli core RNAP enzyme (Epicentre) was
purchased from Cambio. Protein concentration was
estimated using the Lowry method.33
Affinity chromatography with immobilised His-PspAFL
or His-PspAfragments
Affinity chromatography was performed at room
temperature in Micro Biospin® Bio-Rad columns packed
with 50 μl of Ni-NTA agarose (Qiagen). His-PspAFL or
His-PspAfragments (500 μl of 6 μM) were bound to the
columns. The columns were then washed with 20 vol ofbuffer A containing 20 mM Tris–HCl (pH 8.0), 50 mM
NaCl, and 15 mM MgCl2±1 mM nucleotide (AMPPNP,
ATPγS, ATP, ADP, or AMP). PspF1–275WT or W56A
(200 μl at 20 μM) was added, and the unbound protein
was removed by washing with 5× 2 vol of buffer A plus
40 mM imidazole±1 mM nucleotide. His-tagged PspA
(full length or fragments) was eluted with 2× 2 vol of
buffer A containing 500 mM imidazole. One-hundred-
microliter fractions were collected, and 20 μl was analysed
by 12% SDS-PAGE (acrylamide/bisacrylamide, 37.5:1).
ATPase activity
ATPase activity assays were performed at a final
volume of 10 μl in a buffer containing 35 mM Tris-acetate
(pH 8.0), 70 mM potassium acetate, 15 mM magnesium
acetate, 19 mM ammonium acetate, 0.7 mM DTT, and
1 μM PspF1–275±PspA full-length or fragments (as indicat-
ed). The mix was incubated at 37 °C for 10 min, and the
reaction was started by adding 3 μl of an ATP solution
containing 0.6 μCi/μl [α-32P]ATP (3000 Ci/mmol) and
0.1 mM ATP. The reactions were incubated at 37 °C for
different times and then quenched by addition of 5 vol of
2 M formic acid. [α-32P]ADP was separated from ATP by
thin-layer chromatography, and radiolabelled ADP and
ATP were measured by PhosphorImager (Fuji FLA-5000)
and analysed using Aida software. Activity is expressed as
percentage turnover compared to PspF1–275WT. All experi-
ments were carried out independently at least in triplicate,
and fluctuations of turnover values were maximally 10%.
Gel filtration through Superdex 200 or Superose 6
PspF1–275WT or variants and PspAFL or PspAfragments
(as indicated) were incubated for 10 min at 4 °C in a buffer
containing 20 mM Tris–HCl (pH 8.0), 50 mM NaCl, and
15 mMMgCl2. Fifty-microliter samples were then injected
onto a Superdex 200 column (10 mm×300 mm, 24 ml; GE
Healthcare) or a Superose 6 column (10 mm×300 mm,
24 ml; GE Healthcare) installed on an AKTA system (GE
Healthcare) and equilibrated with the sample buffer.
Chromatography was performed at 4 °C at a flow rate of
0.5 ml/min, and columns were calibrated with the
globular proteins thyroglobulin (669 kDa), apoferritin
(443 kDa), β-amylase (200 kDa), bovine serum albumin
(66 kDa), and carbonic anhydrase (29 kDa). All experi-
ments were repeated at least two times, and the elution
profiles obtained were similar. Proteins were detected at a
wavelength of 280 nm (mAU: milli absorbance unit at
280 nm).
Native gel mobility shift assay
Gel mobility shift assays were conducted to detect
protein–protein or protein–DNA complexes. Assays were
performed at a final volume of 10 μl containing 10 mM
Tris-acetate (pH 8.0), 50 mM potassium acetate, 8 mM
magnesium acetate, 0.1 mM DTT, and 4 mM ADP±NaF
(5 mM)±HMK-σ54 (radiolabelled) (1 μM). Where re-
quired, PspF1–275WT or W56A (2 μM), with or without
different concentrations of full-length PspA or PspA
fragments (as indicated), was added and incubated for
5 min at 37 °C. After addition of 0.4 mMAlCl3, the reaction
mixture was incubated for 20 min at 37 °C to allow in situ
formation of metal–fluoride analogues. Complexes were
analysed on a native 4.5% polyacrylamide (acrylamide/
bisacrylamide, 37.5:1) gel run in TG buffer [25 mM Tris–
774 PspA-PspF Regulatory ComplexHCl (pH 8.3) and 192 mM glycine]. Radiolabelled protein
complexes were detected by PhosphorImager (Fuji Bas-
5000) and analysed using the Aida software.Acknowledgements
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